SCRIPT

Pathophysiology of Hairy Cell Leukemia

[Slide 1: Introduction]
Moving onto the pathophysiology of Hairy Cell Leukemia, I’ll be focusing on three key points: genetic and molecular mechanisms, bone marrow infiltration, and splenic involvement.

[Slide 2: Genetic and Molecular Pathogenesis]
As mentioned before, Hairy Cell Leukemia is primarily driven by the B-RAF V600E mutation, leading to abnormal activation of the MAPK/ERK pathway, causing uncontrolled cell growth. This results in clonal B-cell proliferation, inhibited apoptosis, and altered adhesion properties, leading to cell accumulation in the bone marrow and spleen. In B-RAF-negative cases, MAP2K1 mutations may also contribute to disease progression.

The diagram illustrates how the B-RAF mutation drives uncontrolled cell growth and how B-RAF and MEK inhibitors block this process.

[Slide 3: Bone Marrow Infiltration and Fibrosis]
Hairy cells infiltrate the bone marrow, suppressing normal hematopoiesis. They also secrete TGF-β, which activates fibroblasts, leading to marrow fibrosis. This often results in a dry tap on bone marrow aspiration and leads to pancytopenia, which causes:

  • Anemia (↓ RBCs) → Leading to fatigue and pallor

  • Neutropenia (↓ WBCs) → Leading to an increase in infections 

  • Thrombocytopenia (↓ Platelets), potentially increasing the risk of bleeding.

[Slide 4: Splenic Involvement]
Hairy cells primarily infiltrate the red pulp of the spleen, unlike other leukemias. This leads to splenomegaly, causing hypersplenism, which worsens cytopenia by trapping and destroying blood cells. Furthermore, an enlarged spleen can compress the stomach, leading to early satiety and weight loss.

Conclusion:

To conclude, Hairy Cell Leukemia is a rare, chronic B-cell malignancy characterized by pancytopenia, splenomegaly, and the presence of distinctive 'hairy' lymphocytes. The B-RAF V600E mutation is a key pathogenic driver and an important diagnostic marker.

First-line therapies, such as Cladribine and Pentostatin, are highly effective but can induce prolonged immunosuppression. In refractory or relapsed cases, Rituximab and B-RAF inhibitors offer additional therapeutic options.

And while prognosis is generally positive with high response rates, disease recurrence remains a clinical challenge. Ongoing research into more precise treatments may lead to even better long-term outcomes.